NRG Oncology NRG-GI007 trial-in-progress: Phase I study of OBP-301 (Telomelysin) and definitive chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery.
Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Theodore S. Hong(Massachusetts General Hospital), David H. Ilson(Memorial Sloan Kettering Cancer Center), Terence M. Williams(City Of Hope National Medical Center), Makoto Nishimura(Memorial Sloan Kettering Cancer Center), Adam D. Yock(Vanderbilt University Medical Center), Kathryn Winter(RTOG Foundation), Prasad S. Adusumilli(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
|Journal of Clinical Investigation|2016|1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914